These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17664326)

  • 1. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.
    Yadav AB; Misra A
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3740-2. PubMed ID: 17664326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy.
    Yadav AB; Sharma R; Muttil P; Singh AK; Verma RK; Mohan M; Patel SK; Misra A
    Indian J Exp Biol; 2009 Jun; 47(6):469-74. PubMed ID: 19634713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
    Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
    Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection.
    Grenha A; Alves AD; Guerreiro F; Pinho J; Simões S; Almeida AJ; Gaspar MM
    Eur J Pharm Biopharm; 2020 Feb; 147():38-44. PubMed ID: 31790800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhalable microparticles containing large payload of anti-tuberculosis drugs.
    Muttil P; Kaur J; Kumar K; Yadav AB; Sharma R; Misra A
    Eur J Pharm Sci; 2007 Oct; 32(2):140-50. PubMed ID: 17681458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.
    Sharma R; Muttil P; Yadav AB; Rath SK; Bajpai VK; Mani U; Misra A
    J Antimicrob Chemother; 2007 Mar; 59(3):499-506. PubMed ID: 17242031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.
    Verma RK; Kaur J; Kumar K; Yadav AB; Misra A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3195-201. PubMed ID: 18591268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
    Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
    Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The receptor-mediated uptake, survival, replication, and drug sensitivity of Mycobacterium tuberculosis within the macrophage-like cell line THP-1: a comparison with human monocyte-derived macrophages.
    Stokes RW; Doxsee D
    Cell Immunol; 1999 Oct; 197(1):1-9. PubMed ID: 10555990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles.
    Singh AK; Abhimanyu ; Yadav AB; Sharma S; Garg R; Bose M; Misra A
    Pharmacogenomics; 2013 Apr; 14(5):531-40. PubMed ID: 23556450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
    Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment.
    Cunha L; Rodrigues S; Rosa da Costa AM; Faleiro L; Buttini F; Grenha A
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1313-1320. PubMed ID: 30990096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complex research studies in the testing of the effectiveness of phenaside].
    Sel'tsovskiĭ PP; Irtuganova OA; Slogotskaia LV; Smirnova NS; Moroz AM; Borzenko AS; Spasov AA; Smirnova LA; Dzhura PI; Karpov AV; Ivanovskiĭ VB; Pauker MN; Plemiannikova GI
    Probl Tuberk; 2001; (8):29-31. PubMed ID: 11767386
    [No Abstract]   [Full Text] [Related]  

  • 20. Spray-dried fucoidan microparticles for pulmonary delivery of antitubercular drugs.
    Cunha L; Rosa da Costa AM; Lourenço JP; Buttini F; Grenha A
    J Microencapsul; 2018 Jun; 35(4):392-405. PubMed ID: 30112917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.